An Open-Label, Single-Dose Study to Compare the Pharmacokinetics (PK) of an Oromucosal Dose of Four Sprays of Sativex in Subjects With Severe Renal Impairment or End Stage Renal Disease (ESRD), Not Requiring Dialysis, Compared to Matched Subjects With Normal Renal Function.

Trial Profile

An Open-Label, Single-Dose Study to Compare the Pharmacokinetics (PK) of an Oromucosal Dose of Four Sprays of Sativex in Subjects With Severe Renal Impairment or End Stage Renal Disease (ESRD), Not Requiring Dialysis, Compared to Matched Subjects With Normal Renal Function.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Cancer pain; Glioblastoma; Muscle spasticity; Neuropathic pain
  • Focus Pharmacokinetics
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 10 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 13 Aug 2015 Planned End Date changed from 1 Jan 2016 to 1 Oct 2016, as reported by ClinicalTrials.gov.
    • 13 Aug 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Oct 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top